GlassScriptPhysician profile
Thomas L Martin
NPI 1417908922
$2,214.67
in general payments reported to CMS, 2019-2025
24 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $53.49 · 2021: $195 · 2022: $407 · 2023: $325 · 2024: $305 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.61 | 2019-2025 | |
| Janssen Biotech, INC. | $504.62 | 2019-2025 | Tremfya |
| Depuy Synthes Sales INC. | $145.18 | 2025 | Attune, Actis, Inhance |
| Takeda Pharmaceuticals U.S.A., INC. | $118.12 | 2019-2025 | Eohilia, Entyvio |
| Celgene Corporation | $101.76 | 2023-2024 | Zeposia |
| Lumendi LLC | $92.55 | 2025 | |
| Lilly USA, LLC | $92.32 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $70.91 | 2024-2025 | Voquezna |
| Pfizer INC. | $63.13 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $44.42 | 2020-2023 | Zinplava, Dificid |
| Organon LLC | $38.99 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $38.28 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $35.14 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $30.89 | 2025 | Iqirvo |
| Boston Scientific Corporation | $29.97 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $22.20 | 2023 | Rapide Balloon, Inflation Device |
| Genzyme Corporation | $20.94 | 2023 | |
| Ucb, INC. | $18.47 | 2024 | Cimzia |
| Amgen INC. | $17.65 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.26 | 2022 | |
| Celltrion USA INC. | $15.83 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $13.62 | 2020 | |
| Intercept Pharmaceuticals, INC. | $11.96 | 2022 | |
| Allergan, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.